Literature DB >> 3071459

Comparative double-blind study of ketanserin versus propranolol in the treatment of essential hypertension.

K Ito1, T Omae, M Ikeda, O Iimura, K Yoshinaga, M Ishii, Y Kaneko, Y Mizuno, Y Masuyama, T Takeda.   

Abstract

To clarify the antihypertensive effect, safety and clinical usefulness of ketanserin, a comparative double-blind study was carried out in 277 patients with essential hypertension using propranolol as a control drug. Ketanserin 10 to 30 mg twice daily and propranolol 20 to 40 mg 3 times daily were administered for 12 weeks. The results showed no difference in antihypertensive effect and clinical usefulness between the drugs. In the ketanserine group, plasma concentration of total cholesterol was decreased significantly, and the reduction in heart rate was less than in the propranolol group. These findings suggest that ketanserin may satisfactorily control blood pressure.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3071459     DOI: 10.2165/00003495-198800361-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  3 in total

1.  Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors.

Authors:  J E Leysen; F Awouters; L Kennis; P M Laduron; J Vandenberk; P A Janssen
Journal:  Life Sci       Date:  1981-03-02       Impact factor: 5.037

2.  The effect of ketanserin on blood pressure and biochemical parameters in treated patients with essential hypertension.

Authors:  L M Wing; J P Chalmers; M J West; A J Bune; B Ayres; J R Graham
Journal:  Clin Exp Hypertens A       Date:  1984

3.  Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor.

Authors:  J R Seibold; A H Jageneau
Journal:  Arthritis Rheum       Date:  1984-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.